期刊档案 · 医学-药学
Current Pharmaceutical Analysis
ISSN 1573-4129 · eISSN 1875-676X · Bentham Science Publishers B.V. · U ARAB EMIRATES · Quarterly · 创刊 2005
Current Pharmaceutical Analysis 中科院 医学 4区（2025 年升级版），影响因子 3.59，混合开放获取，APC 约 2,100 美元，投稿社区反馈审稿约 2 个月，录用比例约50%（社区反馈），2025 年发文 57 篇，SCIE、Scopus 收录。
研究范围
研究范围与定位
Current Pharmaceutical Analysis 由 Bentham Science Publishers B.V. 出版，属中科院医学大类（2025 升级版4区）。按 OpenAlex 近年发文统计，该刊主要发表 Analytical Methods in Pharmaceuticals、Analytical Chemistry and Chromatography、Antibiotics Pharmacokinetics and Efficacy 等主题的论文，这 3 个主题约占 47.8%。（根据 OpenAlex 主题统计与中科院分区数据生成）
Volumes 1-20 of Current Pharmaceutical Analysis, published by Bentham Science, can be accessed here: https://www.benthamscience.com/journal/cpa. Current Pharmaceutical Analysis publishes full-length/mini reviews and original research articles on all the most recent advances in pharmaceutical and biomedical analysis. All aspects of the field are represented including drug analysis and pharmacological research. The journal is essential to all involved in pharmaceutical, biochemical, biomedicine and clinical analysis.This journal contains four sections:Section A (Pharmaceutical Science): This section focuses on the discovery, development, evaluation, and regulation of medications and therapies. Its main goal is to enhance human health by developing new pharmaceutical products, refining drug delivery methods, and ensuring both the safety and effectiveness of treatments.Section B (Toxicology and Pharmaceutics): This section focuses on the formulation, development, and toxicology response of drugs. It encompasses the design and testing of drug delivery systems to ensure optimal absorption, distribution, effectiveness and toxicity of medications in the body.Section C (Pharmaceutical Biotechnology): This section focuses on the utilizing biological systems, processes, or organisms to create drugs and treatments. It encompasses the development of biopharmaceuticals, including vaccines, monoclonal antibodies, gene therapies, and bionanotechnology. Additionally, it involves the application of bioengineering methods to alter cells and microorganisms for therapeutic applications.Section D (Drug Discovery): This section focuses on the identification, design, and development of new pharmaceutical compounds aimed at treating various diseases. It involves investigating novel chemical entities, natural substances, and biological molecules, utilizing methods such as high-throughput screening, molecular modeling, and structure-based drug design. The main goal is to discover safe, effective, and targeted treatments by comprehending disease mechanisms and refining lead compounds through preclinical evaluation.Editorial Board
摘自期刊官网 Aims & Scope
研究方向（LetPub）：医学-药学
主要研究主题 OpenAlex 近年发文统计，占比为近似值
- Analytical Methods in PharmaceuticalsChemistry21.7%
- Analytical Chemistry and ChromatographyChemistry20.6%
- Antibiotics Pharmacokinetics and EfficacyMedicine5.6%
- Electrochemical sensors and biosensorsEngineering4.2%
- Computational Drug Discovery MethodsComputer Science3.9%
- Pesticide Residue Analysis and SafetyAgricultural and Biological Sciences3.4%
- Traditional Chinese Medicine AnalysisMedicine3.3%
- Metabolomics and Mass Spectrometry StudiesBiochemistry, Genetics and Molecular Biology3.2%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表（ 2025年3月升级版）医学 4 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 4 区 |
| 小类 | 药学PHARMACOLOGY & PHARMACY | 4 区 |
Top 期刊：否综述期刊：否
《新锐期刊分区表》（ 2026年3月发布）医学 4 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 4 区 |
| 小类 | 药学PHARMACOLOGY & PHARMACY | 4 区 |
Top 期刊：否综述期刊：未标注
期刊分区表（ 2023年12月旧的升级版）医学 4 区
| 类别 | 学科 | 分区 |
|---|---|---|
| 大类 | 医学 | 4 区 |
| 小类 | 药学PHARMACOLOGY & PHARMACY | 4 区 |
Top 期刊：否综述期刊：否
数据库收录
SCIEScopusLetPub
国际期刊预警名单：各版本均未列入LetPub
不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- 影响因子
- 3.59LetPub ·
- 影响因子（出版商公布） 2025
- 3.6出版商官网 ·
- CiteScore 2026-06
- 2.7LetPub ·
- SJR 2026-06
- 0.44LetPub ·
- SNIP 2026-06
- 0.47LetPub ·
- h-index
- 22LetPub ·
- h-index
- 35OpenAlex ·
- i10-index
- 241OpenAlex ·
- 两年平均被引
- 4.06OpenAlex ·
- 自引率
- 0%LetPub ·
- Gold OA 文章占比
- 23.96%LetPub ·
发文规模
- 年文章数
- 40LetPub ·
逐年发文量 OpenAlex 统计 · 累计 1,377 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 68 | 68 | 15 |
| 2025 | 57 | 56 | 189 |
| 2024 | 93 | 11 | 681 |
| 2023 | 51 | 2 | 243 |
| 2022 | 53 | 4 | 242 |
| 2021 | 54 | 4 | 195 |
不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
文章统计的审稿周期 Crossref 登记的稿件日期 · 至
样本不足近 24 个月只有 7 篇文章登记了投稿与接收日期，不足以给出中位数
只统计最终被录用并发表的文章，不含被拒稿件的处理时间，因此通常长于出版商公布的"首次决定时间"。
其他来源
- 平均审稿速度（社区反馈）
- 平均2月LetPub ·
- 平均录用比例（社区反馈）
- 50%LetPub ·
- 录用率（出版商公布）
- 23%出版商官网 ·
- 投稿到首次决定
- 4 天出版商官网 ·
- 接收到发表
- 2 天出版商官网 ·
- 评审方式
- 单盲同行评审出版商官网
社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
混合开放获取LetPub
订阅期刊，作者可付费选择开放获取发表。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| OpenAlex | USD 2,100 | — | — | |
| 出版商官网 | 有，金额未公布 | — | — |
混合期刊的文章处理费仅在作者选择开放获取发表时收取；按订阅方式发表通常不收费。
费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。
投稿要求
文章类型与投稿政策（官网）
投稿准备要点1 项，摘自作者指南
- 摘要
- ≤ 300 词
接收的文章类型10 种，含篇幅限制
- commentaryCommentary Expert opinions on published works or the current state of a field, including references. 800–3000 words, no abstract in the main text未说明篇幅
- correspondenceCorrespondence A letter or reply sent to the journal to raise points of interest, discuss differing opinions, or encourage participation 800–3000 words, no abst…未说明篇幅
- editorialEditorial An overview or opinion on a particular issue conveyed by an editor or someone invited by the editor 800–3000 words, no abstract in the main text未说明篇幅
- full length articleFull Length Article A report on new research findings or conceptual analysis that makes a significant contribution to knowledge 4000–8000 words未说明篇幅
- letterArticle TypeDescriptionLengthFull Length ArticleA report on new research findings or conceptual analysis that makes a significant contribution to knowledge4000–…未说明篇幅
- letter to the editorArticle TypeDescriptionLengthFull Length ArticleA report on new research findings or conceptual analysis that makes a significant contribution to knowledge4000–…未说明篇幅
- opinionArticle TypeDescriptionLengthFull Length ArticleA report on new research findings or conceptual analysis that makes a significant contribution to knowledge4000–…正文 ≤ 12,000 词
- research reportArticle TypeDescriptionLengthFull Length ArticleA report on new research findings or conceptual analysis that makes a significant contribution to knowledge4000–…未说明篇幅
- review articleReview Article An overview of the development of a field or current thinking. It integrates multiple sources of information and includes many citations. It emph…未说明篇幅
- short communicationShort Communication A concise format for observations and research reports. 1500–3000 words未说明篇幅
官网政策摘录AI 使用、作者资格、利益冲突、许可与版权、开放获取、同行评审、预印本
- AI 使用 Declaration of generative AI use
作者在投稿时必须声明在稿件准备过程中使用生成式人工智能工具的情况。 模型中文摘要
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
原文 ↗出版商官网 ·- 作者资格 Group authorship
团体署名须在投稿时于标题页声明，通讯作者应代表团体协调所有通讯事宜。 模型中文摘要
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
原文 ↗出版商官网 ·- 利益冲突 Declaration of competing interests
所有作者必须披露可能不当影响或偏袒其工作的财务和个人关系，并完成声明工具。 模型中文摘要
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
原文 ↗出版商官网 ·- 许可与版权 Creative Commons Attribution (CC BY)
该许可允许用户以商业目的分发、复制、改编或挖掘文章内容，但须注明出处、附许可链接并说明是否修改。 模型中文摘要
Allows users to: distribute and copy the article; create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation); include in a collective work (such as an anthology); and text or data mine the article. These uses are permitted even for commercial purposes, provided the user: gives appropriate credit to the author(s) (with a lin…
原文 ↗出版商官网 ·- 开放获取 KeAi Guide for authors: Open Access
本刊为开放获取期刊，所有文章立即永久免费供读者阅读下载，但作者或其资助方需支付文章出版费（APC）。 模型中文摘要
This is an open access journal: all articles will be immediately and permanently free for everyone to read and download. To provide open access, this journal has an open access fee (also known as an article publishing charge APC) which needs to be paid by the authors or on their behalf e.g. by their research funder or institution. Permitted third party (re)use is defined by the following Creative …
原文 ↗出版商官网 ·- 同行评审 Peer review
本刊采用单盲同行评审，投稿先由编辑评估，合适稿件通常送至少两名审稿人独立评审，最终由编辑决定接受与否。 模型中文摘要
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors to determine suitability for publication in this journal. If your submission is deemed suitable, it will typically be sent to a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected will…
原文 ↗出版商官网 ·- 预印本 Preprint sharing
作者可按Elsevier文章共享政策分享预印本，且分享预印本不视为先行发表。 模型中文摘要
Authors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
原文 ↗出版商官网 ·
摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。
基本信息
出版信息与官方入口
- 出版商
- Bentham Science Publishers B.V.
- 出版国家或地区
- U ARAB EMIRATES
- 出版语言
- English
- 出版周期
- Quarterly
- 创刊年份
- 2005
- ISSN
- 1573-4129
- 电子版 ISSN
- 1875-676X
常见问题
关于 Current Pharmaceutical Analysis 的常见问题
Current Pharmaceutical Analysis 是中科院几区期刊？
2025 年升级版分区表中，Current Pharmaceutical Analysis 为医学 4区，小类 药学 4 区。2026 年新锐版分区表中为医学 4区。不同版本与大小类分区不能混用。
Current Pharmaceutical Analysis 的影响因子是多少？
LetPub 汇总的最新公布影响因子为 3.59，CiteScore 为 2.7，h-index 为 35。
Current Pharmaceutical Analysis 的审稿周期多长？
投稿社区反馈的平均审稿速度为约 2 个月，平均录用比例反馈为“约50%”；期刊官网公布的录用率为 23%。文章统计只含被录用的稿件，出版商数据口径以官网为准，社区反馈来自投稿者样本，均不代表期刊承诺。
Current Pharmaceutical Analysis 被哪些数据库收录？
据 LetPub 与 DOAJ 记录，Current Pharmaceutical Analysis 被 SCIE、Scopus 收录。
Current Pharmaceutical Analysis 是开放获取期刊吗？版面费多少？
Current Pharmaceutical Analysis 为混合开放获取。选择开放获取发表时APC 约 2,100 美元。
来源与更新
本页事实来自 LetPub、出版商官网、OpenAlex；每个数字旁标注来源与观测日期，冲突数据保留各来源原值。LetPub 原始详情页：查看 ↗（2026-08-26 归档）。最近更新：。